蘭峰，中醫(yī)學(xué)科學(xué)院阜外醫(yī)院，心血管疾病全國(guó)重點(diǎn)實(shí)驗(yàn)室PI，研究員，博士生導(dǎo)師，主要從事心血管病學(xué)基礎(chǔ)和轉(zhuǎn)化研究。2009年獲得北京大學(xué)細(xì)胞生物學(xué)博士。2009-2014年于斯坦福大學(xué)心血管研究所進(jìn)行博士后研究工作。2014年入選中組部“海外高層次人才計(jì)劃”青年項(xiàng)目，獲得國(guó)家基金委優(yōu)秀青年基金。2014-2019年進(jìn)入首都醫(yī)科大學(xué)附屬北京安貞醫(yī)院，任教授，研究員，博導(dǎo)，并獨(dú)立帶領(lǐng)課題組開展遺傳性心臟病生物治療研究。院校引進(jìn)人才。2020年進(jìn)入阜外醫(yī)院，2021年獲批助理教授，2025年獲得國(guó)家自然科學(xué)基金青年科學(xué)基金項(xiàng)目（A類）[原國(guó)家杰出青年科學(xué)基金]。

主要開展遺傳性心臟病研究，建立了首個(gè)肥厚型心肌病 iPS 模型(Cell Stem Cell 2013#, Web of SCI 引用>500)。帶領(lǐng)團(tuán)隊(duì)采用堿基編輯器（Base Editor）最早實(shí)現(xiàn)了肥厚型心肌病模型的胚胎期基因編輯修正治療(Circulation Research，2021*)，和成體遺傳性心律失常的轉(zhuǎn)錄水平的完全修正(Circulation，2024*)，并基于該研究獲批美國(guó)FDA治療LQT3的孤兒藥認(rèn)定。以通訊作者在European Heart Journal (2025*)，Circulation (2024*)、Nature Biomedical Engineering (2023*)、Science Advances (2023*)、Circulation Research (2021*)、Cell Discovery (2024*)、Bioactive Material (2021*)、Nature Communication (2019*, 2018*)，Cell Death Differentiation (2019*)等高水平雜志發(fā)表論文50篇。 獲批國(guó)際專利一項(xiàng)，中國(guó)發(fā)明專利6項(xiàng)。

久久综合九色欧美综合狠狠_伊人热热久久原色播放WWW_成A人片亚洲日本久久_久久不见久久见免费影院www日本_97久久精品人人做人人爽,又色又爽又黄的视频在线观看,狼群影院视频在线观看高清版,亚洲AV无码精品网站性色,国产乱码久久久久久红粉影视,精品国产乱码久久久久久一区二区,国产精品免费视频网站,国产A级毛片久久久久久精品,一级特黄高清aaaa大片,亚洲中文字幕欧美一区,久久精品国产99久久狂热,黑人巨大精品欧美_黑人巨大精品欧美黑寡妇_黑人巨大精品欧美一区二区_黑人巨大精品欧美一区二区免费_黑人巨大跨种族video_黑人巨大无码中文字幕无码_黑人巨茎大战俄罗斯美女_黑人巨茎大战俄罗斯美女,中文字幕av不卡|亚洲欧美国产另类|天天干在线播放|日韩黄视频|欧美七区|可以免费看毛片的网站|黄色片在线|国产精品96久久久久久

1．Qi M#, Ma S# Liu J#, Liu X, Wei J, Lu W, Zhang S, Chang Y, Zhang Y, Zhong K, Yan Y, Zhu, M, Song Y, Chen Y, Hao G, Wang J, Wang L, Lee A, Chen X, Wang Y*, Lan F*. In vivo base editing of Scn5a rescues type 3 long QT syndrome in mice. Circulation. 2024, 149(4): 317-332. (IF=37.8)

2．Wang Y, Qi T, Liu J, Yang Y, Wang Z, Wang Y, Wang T, Li M, Li M, Lu D, Chang ACY, Yang L, Gao S, Wang Y, Lan F*. A highly specific CRISPR-Cas12j nuclease enables allele-specific genome editing. Sci Adv. 2023 Feb 10;9(6). (IF=13.6)

3．You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Tong Y, Estania AP, Cao J, Hsu WH, Liu Y, Chiang CL, Schrank BR, Huntoon K, Lee D, Li Z, Zhao Y, Zhang H, Gallup TD, Ha J, Dong S, Li X, Wang Y, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F*, Kim BYS*, Lee AS*. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat Biomed Eng. 2023 Jul;7(7):887-900 (IF=28.1)

4．Zhou P, Feng Fa, Song Y, Lia J, Li Q, Xu Z, Shi J, Qin L, He F, Li H, Han Y, Zhang R, Liu H*, Lan F*. Novel RGD-containing peptides exhibited improved abilities to integrin receptor binding and cultures of human induced pluripotent stem cells. Materials & Design. 2022 July 219:110762. (IF=9.4167)

5．Ma S, Jiang W, Liu X, Lu W, Qi t, Wei J, Wu F, Chang Y, Zhang S, Song Y, Bai R, Wang J, Lee A, Zhang H*, Wang Y*, Lan F*. Efficient correction of a hypertrophic cardiomyopathy mutation by ABEmax-NG. Circulation Research, 2021, Oct 29;129(10):895-908. (IF=20.1)

6．Guo R; Wan F; Xu Q; Feng T; Yang H; Gong Y; Ma S; Chang Y; Zhang S; Jiang Y, Wang H; Chang D; Zhang H; Ling Y*; Lan F*. Cell sheet formation enhances the therapeutic effects of human umbilical cord mesenchymal stem cells on myocardial infarction as a bioactive material. Bioactive Material, 2021, Mar 5;6(9):2999-3012. (IF=18.9)

7．Jiang Y, Li X, Guo T, Lu WJ, Ma S, Chang Y, Song Y, Zhang S, Bai R, Wang H, Qi M, Jiang H*, Zhang H*, Lan F*. Ranolazine rescues the heart failure phenotype of PLN-deficient human pluripotent stem cell-derived cardiomyocytes. Stem Cell Reports. 2022 Apr 12;17(4):804-819. (IF=5.9)

8．Wang D, Zhang C, Wang B, Li B, Wang Q, Liu D, Wang H, Zhou Y, Shi L, Lan F*, Wang Y*. Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning. Nature Communication. 2019 Sep 19;10(1):4284. (IF= 16.6)

9．Lan F#, Lee AS#, Liang P#, Sanchez-Freire V, Nguyen PK , Wang L, Han L, Yen M, Wang Y, Sun N, Abilez OJ, Navarrete EG, Wheeler M, Lewis R, Yamaguchi Y, Ashley EA, Bers DM, Robbins RC, Longaker MT, Wu JC. Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. Cell Stem Cell. 2013;12:101-113. (IF= 23.9)

10．Lan F#, Liu J#, Narsinh KH, Hu S, Han L, Lee AS, Karow M, Nguyen PK, Nag D, Calos MP, Robbins RC, Wu JC*. Safe genetic modification of cardiac stem cells using a site-specific integration technique. Circulation. 2012;126:S20-28 (IF=37.8)